Filtered By:
Source: Asian Pacific Journal of Cancer Prevention
Drug: Gleevec
This page shows you your search results in order of date.
Order by Relevance | Date
Total 13 results found since Jan 2013.
CD34+/CD38- Stem Cell Burden Could Predict Chronic Myeloid Leukemia Patients' Outcome
CONCLUSION: The percentage of CD34+/CD38- SCs burden at diagnosis reflects the CML disease behavior and is considered a biomarker for predicting CML patients' response to first-line Tyrosine kinase inhibitors (TKI) therapy.PMID:34711000 | DOI:10.31557/APJCP.2021.22.10.3237
Source: Asian Pacific Journal of Cancer Prevention - October 29, 2021 Category: Cancer & Oncology Authors: Noura Fathy El-Metwaly Salah Aref Mohamed Ayed Manal Abdel Hamid Ahmed M A El-Sokkary Source Type: research
